Oxaprozin pharmacokinetics

Davies N. M. Clinical pharmacokinetics of oxaprozin, Clin. Pharmacokinet. 1998b, 35, 425-436. 

Example Ibuprofen (Motrin, Advil, Nuprin) naproxen (Naprosyn) (Aleve is a similar OTC drug) Oxaprozin (Daypro) ketoprofen (Orudis). Route PO Pregnancy category B Pharmacokinetic Absorbed from the GI tract, metabolized in the liver and primarily excreted in urine ... 

Oxaprozin (Daypro) has similar pharmacological properties, adverse effects, and therapeutic uses to those of other propionic acid derivatives. However, its pharmacokinetic properties differ considerably. Peak plasma levels are not achieved until 3 to 6 hours after an oral dose, whereas its half-life of 40 to 60 hours allows for once-daily adminisffation. 

The manufacturer of spirapril briefly noted in a review that there was no relevant pharmacokinetic interaction between spirapril and diclofenac. Oxaprozin 1.2 g daily for 3 weeks did not affect the pharmacokinetics of enalapril 10 to 40 mg daily in 29 patients with hypertension. A brief mention is made in a review that, in healthy subjects, the pharmacokinetics of ramipril were unaffected by indometacin [dosage not stated] given for 3 days. ... 

Oral contraceptives increase diflunisal clearance in women, but only to the level normally seen in men. One study showed modestly reduced levels of ibuprofen with oral contraceptives, but another study did not. Oral contraceptives reduced the levels of aspirin, but not phenylbutazone. There are no clinically relevant changes in the pharmacokinetics of oxaprozin with conjugated oestrogens. 

There was no difference in the pharmacokinetics of a single 1.2-g dose of oxaprozin in 11 women taking conjugated oestrogens (Premarin) than in 11 control women, except that the time to peak concentration was shorter (4 versus 8.9 hours). This difference is unlikely to be of clinical importance. 

Scavone JM, Ochs HR, Greenblatt DJ, Matlis R. Pharmacokinetics of oxaprozin in women receiving conjugated estrogen. Eur J Clin Pharmacol 9ZZ) 35, 105-8. 

---

See also in sourсe #XX -- [ ]

---